Scalper1 News
Big pharma Merck (MRK) said Tuesday that it will stop a phase-three trial of cancer drug Keytruda for melanoma because the trial had already met its goals ahead of schedule. Merck’s stock rose about 1% in early trading. The trial, called Keynote-006, compared Keytruda head to head with Bristol-Myers Squibb’s (BMY) Yervoy, currently the standard of care for melanoma, in previously untreated patients. Merck said that the trial had met its endpoints Scalper1 News
Scalper1 News